Floatz logo

gsk1120212

Glioma, Diffuse Midline, H3K27M-mutant

St. Jude Children's Research HospitalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Glioma, Diffuse Midline, H3K27M-mutant cohort.

Asset / SponsorPhaseRating
Ribociclib
Nationwide Children's Hospital
Phase 2B
Olutasidenib
Rigel Pharmaceuticals
Phase 2CCC
Everolimus
Nationwide Children's Hospital
Phase 2CCC
Pegargiminase
Sabine Mueller, MD, PhD
Phase 1/2CC
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant
BB
Indicative ·
69 / 100
View asset →
Glioma, High GradeDormant
BB
Indicative ·
69 / 100
View asset →
anaplastic oligodendrogliomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →